Boahene K A, Klein G J, Yee R, Sharma A D, Fujimura O
Department of Medicine, University Hospital, London, Ontario, Canada.
J Am Coll Cardiol. 1990 Nov;16(6):1408-14. doi: 10.1016/0735-1097(90)90384-2.
The effects of intravenous procainamide (n = 30) or propafenone (n = 25) were evaluated in 55 patients with acute atrial fibrillation and the Wolff-Parkinson-White syndrome. All patients received either procainamide (12 to 15 mg/kg body weight) or propafenone (1 to 2 mg/kg) during sustained (greater than 10 min) atrial fibrillation or after termination of nonsustained atrial fibrillation. Termination of atrial fibrillation was attributed to a drug if it occurred less than or equal to 15 min after infusion. Measurements included mean cycle length of fibrillatory electrograms (mean AA interval) as measured at the high right atrium and shortest RR interval between pre-excited cycles during atrial fibrillation. Atrial fibrillation terminated more frequently after procainamide administration (65%) than after propafenone (46%), although this difference was not significant. Procainamide prolonged the shortest pre-excited RR interval (228 +/- 41 to 339 +/- 23 ms, p = 0.0001) as did propafenone (215 +/- 40 to 415 +/- 198 ms, p = 0.0001) and the magnitude of increase was greater for propafenone (p = 0.048). Patients with sustained atrial fibrillation had shorter mean AA intervals than did their counterparts with nonsustained atrial fibrillation (123 +/- 25 versus 186 +/- 35 ms, p = 0.0001). Termination of sustained atrial fibrillation by either drug was accompanied by prolongation of the mean AA interval but not necessarily by the shortest pre-excited RR interval. Termination of atrial fibrillation was heralded by a 68% increase in the mean AA interval after procainamide administration compared with a 30% increase when the arrhythmia persisted. For propafenone the increases were 90% and 68%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
对55例急性房颤合并预激综合征患者评估了静脉注射普鲁卡因胺(n = 30)或普罗帕酮(n = 25)的效果。所有患者在持续性(大于10分钟)房颤期间或非持续性房颤终止后,接受了普鲁卡因胺(12至15mg/kg体重)或普罗帕酮(1至2mg/kg)治疗。如果房颤在输注后15分钟内终止,则归因于药物作用。测量指标包括在高位右心房测量的颤动电图平均周期长度(平均AA间期)以及房颤期间预激周期之间的最短RR间期。尽管差异不显著,但普鲁卡因胺给药后房颤终止的频率(65%)高于普罗帕酮(46%)。普鲁卡因胺延长了最短预激RR间期(从228±41毫秒延长至339±23毫秒,p = 0.0001),普罗帕酮也有同样效果(从215±40毫秒延长至415±198毫秒,p = 0.0001),且普罗帕酮的延长幅度更大(p = 0.048)。持续性房颤患者的平均AA间期短于非持续性房颤患者(123±25毫秒对186±35毫秒,p = 0.0001)。两种药物终止持续性房颤均伴有平均AA间期延长,但不一定伴有最短预激RR间期延长。与心律失常持续时平均AA间期增加30%相比,普鲁卡因胺给药后平均AA间期增加68%预示着房颤终止。对于普罗帕酮,增加幅度分别为90%和68%。(摘要截断于250字)